For most adults, cancer screening is a patchwork. The disease state in question, the full set of major adult cancers, kills more than 600,000 Americans each year, and a meaningful share of those deaths involve tumors that were biologically detectable earlier than they were caught. Catch Bio, a Chicago-based healthtech company founded in 2023, is building a consumer product around that gap. It maps an individual's risk factors across every major cancer and generates what it describes as an optimal screening protocol and personalized action plan [Crunchbase].
The patient population Catch is courting is broad: adults who are nominally healthy, have no active diagnosis, and want a more structured answer to the question of what they should actually be screened for and when. Today, the standard of care for that person is a set of population-level guidelines from bodies like the U.S. Preventive Services Task Force and the American Cancer Society, filtered through whatever a primary care physician has time to discuss in a 15-minute visit. Those guidelines are age- and sex-stratified but largely do not personalize to family history depth, germline risk, lifestyle exposures, or biomarker panels in any integrated way.
The bet
Catch's wedge is to sit in that middle and sell directly to the consumer. The company describes its service as a comprehensive cancer risk assessment that evaluates individual risk factors and biomarkers to help users understand and reduce their cancer risk through personalized action plans [f4.fund]. A partner write-up from the Kahn Longevity Center frames it more ambitiously, describing Catch as the first platform to quantify lifetime cancer risk and turn it into an actionable, personalized prevention strategy [Kahn Longevity Center]. The B2C model is notable. Catch is wagering that a meaningful slice of consumers will pay out of pocket for a product that aggregates that work and adds a clear next step.
Why it could be big
The tailwinds here are real. Consumer longevity medicine has moved from a fringe interest to a recognizable category. Multi-cancer early detection blood tests, most prominently Galleri from GRAIL, have made the idea of pan-cancer screening a mainstream conversation. A platform that helps a consumer figure out which of these tests, scans, and specialist visits actually fit their personal risk profile is a plausible orchestration layer on top of a fragmented prevention market. Catch raised roughly $2 million in a seed round disclosed in a January 2025 Form D filing [formds.com, Jan 2025].
| Metric | Value |
|---|---|
| Seed round (Jan 2025) | $2,000,000 |
The team and traction
Public visibility into Catch's team and customer base is early-stage. The company is profiled by f4.fund [f4.fund] and has earned an endorsement post from integrative cardiologist Joel Kahn, MD [Kahn Longevity Center]. PitchBook lists the company as founded in 2023 and headquartered in Chicago [PitchBook]. The company's app is live in a development environment at app-dev.catchbio.com [Catch Bio].
The honest counterfactual
Bears will say that consumer cancer-risk products face a steep evidence bar and a crowded adjacent market. Color Health, Nucleus Genomics, and a wave of longevity clinics already pitch overlapping value propositions, and any tool that influences screening decisions invites scrutiny from clinicians and, eventually, regulators. A risk score that nudges a 40-year-old toward a CT scan they did not need creates real harm: false positives, incidental findings, follow-up biopsies. Without peer-reviewed validation of its risk model against outcomes, Catch's claim to be the first platform to quantify lifetime cancer risk [Kahn Longevity Center] will be tested. Bulls answer that Catch is not positioning itself as a diagnostic. It is positioning itself as a screening protocol and action plan, which is closer to clinical decision support and patient education than to a regulated test.
What to watch
The next 12 months should clarify three things. First, whether Catch ships a generally available consumer product out of its development environment and what it charges for it. Second, whether the company partners with any clinical group beyond longevity-medicine endorsers. Third, whether a Series A materializes on the back of usage data, and which investors lead it. A B2C cancer prevention platform is one of the more ambitious wedges in consumer health.